Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757054 · ClinicalTrials.gov registry record · Phase 4
Fecal Recovery of the Probiotic Bacteria Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) in Healthy Humans Following Daily Consumption of a Probiotic Supplement
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT01757054 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 27 participants.
The verdict
NCT01757054, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
The main hypothesis of this study is that there will be a significant increase of Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis (BB-12) in the stool of healthy humans following daily consumption of a probiotic supplement containing these specific strains of probiotic bacteria.
Interventions
- DIETARY_SUPPLEMENT ProNutrients Probiotic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01757054
The ClinicalTrials.gov registry entry for NCT01757054 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ProNutrients Probiotic is the first listed.
NCT01757054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01757054 about?
NCT01757054 is a clinical study titled "Fecal Recovery of the Probiotic Bacteria Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) in Healthy Humans Following Daily Consumption of a Probiotic Supplement". The main hypothesis of this study is that there will be a significant increase of Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis (BB-12) in the stool of healthy humans following daily consumption of a probiotic supplement containing these specific strains of probiotic bacteria.
What is the current status of trial NCT01757054?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2013-02. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01757054?
The interventions under investigation include: ProNutrients Probiotic (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01757054?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.